The review argues that a patient's own risk profile matters more than broad safety worries when looking at GLP-1 receptor agonists.
Recap by typeshit. Full story at News-Medical.Net.
NSW peptide hospitalisations went from five in July 2025 to over 200 in September 2026, and needle programs say syringe machines are emptying within hours.
Bikman says midface volume drops about 7% for every 10 kg lost, and that bariatric surgery patients see the same change.
A woman with bipolar disorder developed tremor and slurred speech three weeks into Zepbound. An outside expert advises checking lithium levels early, not avoiding the drugs.
8:51
Regan Archibald takes on a common question from people using retatrutide: whether the tiredness some report wears off.
Farm Progress links rising beef demand to GLP-1 users, an unexpected ripple from the weight loss drug boom into agriculture.
Per Reuters, the company says both generic Ozempic versions remain available for diabetes treatment and weight management.
Loading…